MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 30, 2004; DOI: 10.1124/mol.104.001198


0026-895X/04/6604-817-823$20.00
Mol Pharmacol 66:817-823, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.001198v1
66/4/817    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.

The Copper Influx Transporter Human Copper Transport Protein 1 Regulates the Uptake of Cisplatin in Human Ovarian Carcinoma Cells

Alison K. Holzer, Goli Samimi, Kuniyuki Katano, Wiltrud Naerdemann, Xinjian Lin, Roohangiz Safaei, and Stephen B. Howell

Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, California

Cells selected for resistance to cisplatin are often cross-resistant to copper and vice versa, and the major copper influx transporter copper transport protein 1 (CTR1) has been shown to regulate the uptake of cisplatin, carboplatin, and oxaliplatin in yeast. To further define the role of hCTR1 in human tumor cells, the ovarian carcinoma cell line A2780 was molecularly engineered to increase expression of hCTR1 by a factor of 20-fold. Enhanced expression of hCTR1 in the A2780/hCTR1 cells was associated with a 6.5-fold increase in basal steady-state copper content and a 13.7-fold increase in initial copper influx, demonstrating that the exogenously expressed hCTR1 was functional in altering copper homeostasis. The A2780/hCTR1 cells accumulated 46% more platinum after a 1-h exposure to 2 µM cisplatin, and 55% more after a 24 h exposure, than the control A2780/empty vector cells. The initial uptake of cisplatin was 81% higher in the A2780/hCTR1 cells when measured at 5 min. Thus, increased expression of hCTR1 had a substantially larger effect on the cellular pharmacology of copper than cisplatin. Interestingly, the increased uptake of copper and cisplatin was accompanied by only a marginal increase in sensitivity to the cytotoxic effect of copper and cisplatin, and there was no increase in the extent of cisplatin-DNA adduct formation. Thus, although increased expression of hCTR1 mediates greater cellular accumulation of copper and cisplatin, hCTR1 delivers these compounds into intracellular compartments from which they do not have ready access to their key cytotoxic targets.


Received April 6, 2004; accepted June 30, 2004

Address correspondence to: Dr. Stephen B. Howell, Department of Medicine 0058, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0058. E-mail: showell{at}ucsd.edu




This article has been cited by other articles:


Home page
Brief Funct Genomic ProteomicHome page
M. Wang, J. You, K. G. Bemis, T. J. Tegeler, and D. P. G. Brown
Label-free mass spectrometry-based protein quantification technologies in proteomic analysis
Brief Funct Genomic Proteomic, June 25, 2008; (2008) eln031v1.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Sinani, D. J. Adle, H. Kim, and J. Lee
Distinct Mechanisms for Ctr1-mediated Copper and Cisplatin Transport
J. Biol. Chem., September 14, 2007; 282(37): 26775 - 26785.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. K. Holzer and S. B. Howell
The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure.
Cancer Res., November 15, 2006; 66(22): 10944 - 10952.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. K. Holzer, G. H. Manorek, and S. B. Howell
Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin
Mol. Pharmacol., October 1, 2006; 70(4): 1390 - 1394.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
A. K. Holzer, N. M. Varki, Q. T. Le, M. A. Gibson, P. Naredi, and S. B. Howell
Expression of the Human Copper Influx Transporter 1 in Normal and Malignant Human Tissues
J. Histochem. Cytochem., September 1, 2006; 54(9): 1041 - 1049.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, et al.
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity.
Cancer Res., September 1, 2006; 66(17): 8847 - 8857.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X. Lin, T. Okuda, J. Trang, and S. B. Howell
Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells
Mol. Pharmacol., May 1, 2006; 69(5): 1748 - 1754.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. G. Aller and V. M. Unger
Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture
PNAS, March 7, 2006; 103(10): 3627 - 3632.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
I.-S. Song, N. Savaraj, Z. H. Siddik, P. Liu, Y. Wei, C. J. Wu, and M. T. Kuo
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells
Mol. Cancer Ther., December 1, 2004; 3(12): 1543 - 1549.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics